Padcev (enfortumab vedotin-ejfv) - Astellas, Pfizer
Amplification, expression and regulation of Nectin-4 in melanomas and sensitivity to the antibody-drug conjugate enfortumab vedotin (ADO 2026) - Sep 7, 2026 - Abstract #KV 091; Pres time: Sep 9, 2026; 09:00 AM - 04:00 PM; Location: ePoster Self-Study 3; No abstract available 
ADC • Melanoma • Solid Tumor • NECTIN4
https://programme.conventus.de/ado-2026/program/program-points/a89bf5e7-268e-4691-99fc-3acf8e8ba522
 
Sophie Steinbuch; Dorothée Bouschery; Frank Splettstoesser; Jan Kleiner; PD Dr. Stilla Frede; Prof. Jennifer Landsberg; PD Dr. Dimo Dietrich
 
Sep 7, 2026
 
Prev Next